# Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy

> **NCT00857584** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 27 (actual)

## Conditions studied

- Bipolar Disorder
- Bipolar Depression

## Interventions

- **DRUG:** Extended release quetiapine (quetiapine XR)
- **DRUG:** Sertraline
- **DRUG:** adequate mood stabilizer

## Key facts

- **NCT ID:** NCT00857584
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00857584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00857584, "Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00857584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*